AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers

Sun,Xiaobai; Chen,Hong; You,Shuling; Tian,Zhikang; Wang,Zhaoyu; Liu,Fulin; Hu,Wenyi; Zhang,Hao; Zhang,Guoan; Zhao,Hongli; Guo,Qingwei

doi:10.3892/mco.2023.2618

AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers

Authors:
- Xiaobai Sun
- Hong Chen
- Shuling You
- Zhikang Tian
- Zhaoyu Wang
- Fulin Liu
- Wenyi Hu
- Hao Zhang
- Guoan Zhang
- Hongli Zhao
- Qingwei Guo
View Affiliations

Affiliations: Department of Pathology, Jinan Adicon Clinical Laboratory, Jinan, Shandong 250000, P.R. China, Clinical Laboratory, The Third People's Hospital of Jinan, Jinan, Shandong 250132, P.R. China, College of Basic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China, Institute of Forensic Medicine and Laboratory Medicine, Jining Medical University, Forensic Science Center of Jining Medical University, Jining, Shandong 272067, P.R. China, Department of Digestive System, Shandong Institute of Parasitic Diseases, Shandong First Medical University and Shandong Academy of Medical Sciences, Jining, Shandong 272067, P.R. China, Department of Hematology, Jinan Children's Hospital, Jinan, Shandong 250132, P.R. China
Published online on: February 8, 2023 https://doi.org/10.3892/mco.2023.2618
Article Number: 22

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is common worldwide. c‑Myc and AXL are both overexpressed in BC, promoting its progression. The present study aimed to investigate the role of AXL in c‑Myc expression in BC. Overexpression of AXL increased c‑Myc expression while knockdown of AXL decreased c‑Myc expression as determined by western blot analysis. Pharmaceutical inhibition of AXL also suppressed c‑Myc expression. AKT and ERK inhibitor LY294002 and U0126 suppressed c‑Myc expression, respectively. AXL overexpression which activates AKT and ERK signaling, upregulates c‑Myc expression, while kinase‑dead AXL which cannot activate AKT and ERK signaling, does not upregulate c‑Myc expression, emphasizing the important role of these two signaling pathways in c‑Myc upregulation. Finally, expression data of BC tissues from The Cancer Proteome Atlas displayed an association between AXL and c‑Myc. Taken together, the present study revealed that AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in BC.

View Figures

View References

1	Paccez JD, Vogelsang M, Parker MI and Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Int J Cancer. 134:1024–1033. 2014.PubMed/NCBI View Article : Google Scholar
2	Graham DK, DeRyckere D, Davies KD and Earp HS: The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 14:769–785. 2014.PubMed/NCBI View Article : Google Scholar
3	Qu X, Liu G, Zhong X, Li X and Zhang Q: Role of AXL expression in non-small cell lung cancer. Oncol Lett. 12:5085–5091. 2016.PubMed/NCBI View Article : Google Scholar
4	Zhang G, Wang M, Zhao H and Cui W: Function of Axl receptor tyrosine kinase in non-small cell lung cancer. Oncol Lett. 15:2726–2734. 2018.PubMed/NCBI View Article : Google Scholar
5	Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852–860. 2012.PubMed/NCBI View Article : Google Scholar
6	Conacci-Sorrell M, McFerrin L and Eisenman RN: An overview of MYC and its interactome. Cold Spring Harb Perspect Med. 4(a014357)2014.PubMed/NCBI View Article : Google Scholar
7	García-Gutiérrez L, Delgado MD and León J: MYC oncogene contributions to release of cell cycle brakes. Genes (Basel). 10(244)2019.PubMed/NCBI View Article : Google Scholar
8	Bretones G, Delgado MD and León J: Myc and cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015.PubMed/NCBI View Article : Google Scholar
9	Singh AM and Dalton S: The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell. 5:141–149. 2009.PubMed/NCBI View Article : Google Scholar
10	Gómez-Casares MT, García-Alegria E, López-Jorge CE, Ferrándiz N, Blanco R, Alvarez S, Vaqué JP, Bretones G, Caraballo JM, Sánchez-Bailón P, et al: MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). Oncogene. 32:2239–2246. 2013.PubMed/NCBI View Article : Google Scholar
11	Stine ZE, Walton ZE, Altman BJ, Hsieh AL and Dang CV: MYC, metabolism, and cancer. Cancer Discov. 5:1024–1039. 2015.PubMed/NCBI View Article : Google Scholar
12	Dang CV: MYC on the path to cancer. Cell. 149:22–35. 2012.PubMed/NCBI View Article : Google Scholar
13	Hong J, Maacha S and Belkhiri A: Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol. 12:2191–2208. 2018.PubMed/NCBI View Article : Google Scholar
14	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
15	Padayachee J, Daniels A, Balgobind A, Ariatti M and Singh M: HER-2/neu and MYC gene silencing in breast cancer: Therapeutic potential and advancement in nonviral nanocarrier systems. Nanomedicine (Lond). 15:1437–1452. 2020.PubMed/NCBI View Article : Google Scholar
16	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012.PubMed/NCBI View Article : Google Scholar
17	Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, et al: Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 107:1124–1129. 2010.PubMed/NCBI View Article : Google Scholar
18	Chang H, An R, Li X, Lang X, Feng J and Lv M: Anti-Axl monoclonal antibodies attenuate the migration of MDA-MB-231 breast cancer cells. Oncol Lett. 22(749)2021.PubMed/NCBI View Article : Google Scholar
19	Meyer AS, Miller MA, Gertler FB and Lauffenburger DA: The receptor AXL Diversifies EGFR signaling and limits the response to EGFR-Targeted inhibitors in triple-negative breast cancer cells. Sci Signal. 6(ra66)2013.PubMed/NCBI View Article : Google Scholar
20	Khera L and Lev S: Accelerating AXL targeting for TNBC therapy. Int J Biochem Cell Biol. 139(106057)2021.PubMed/NCBI View Article : Google Scholar
21	Han S, Wang Y, Ge C, Gao M, Wang X, Wang F, Sun L, Li S, Dong T, Dang Z, et al: Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma. Exp Ther Med. 20(41)2020.PubMed/NCBI View Article : Google Scholar
22	Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R and Melillo RM: Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res. 71:1792–1804. 2011.PubMed/NCBI View Article : Google Scholar
23	Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW, et al: TCPA: A resource for cancer functional proteomics data. Nat Methods. 10:1046–1047. 2013.PubMed/NCBI View Article : Google Scholar
24	Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ and Wheeler DL: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 10(eaag1064)2017.PubMed/NCBI View Article : Google Scholar
25	Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al: R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70:1544–1554. 2010.PubMed/NCBI View Article : Google Scholar
26	Linger RM, Keating AK, Earp HS and Graham DK: TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 100:35–83. 2008.PubMed/NCBI View Article : Google Scholar
27	Blancato J, Singh B, Liu A, Liao DJ and Dickson RB: Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer. 90:1612–1619. 2004.PubMed/NCBI View Article : Google Scholar
28	He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science. 281:1509–1512. 1998.PubMed/NCBI View Article : Google Scholar
29	Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O'Neil J, Neuberg D, Weng AP, et al: NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA. 103:18261–18266. 2006.PubMed/NCBI View Article : Google Scholar
30	Casey SC, Baylot V and Felsher DW: The MYC oncogene is a global regulator of the immune response. Blood. 131:2007–2015. 2018.PubMed/NCBI View Article : Google Scholar